Abstract

Repulsive guidance molecule-a (RGMa), a glycosylphosphatidylinositol-anchored membrane protein, has diverse functions in axon guidance, cell patterning, and cell survival. Inhibition of RGMa attenuates pathological dysfunction in animal models of central nervous system (CNS) diseases including spinal cord injury, multiple sclerosis, and neuromyelitis optica. Here, we examined whether antibody-based inhibition of RGMa had therapeutic effects in a mouse model of Parkinson’s disease (PD). We treated mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and found increased RGMa expression in the substantia nigra (SN). Intraventricular, as well as intravenous, administration of anti-RGMa antibodies reduced the loss of tyrosine hydroxylase (TH)-positive neurons and accumulation of Iba1-positive microglia/macrophages in the SN of MPTP-treated mice. Selective expression of RGMa in TH-positive neurons in the SN-induced neuronal loss/degeneration and inflammation, resulting in a progressive movement disorder. The pathogenic effects of RGMa overexpression were attenuated by treatment with minocycline, which inhibits microglia and macrophage activation. Increased RGMa expression upregulated pro-inflammatory cytokine expression in microglia. Our observations suggest that the upregulation of RGMa is associated with the PD pathology; furthermore, inhibitory RGMa antibodies are a potential therapeutic option.

Highlights

  • Parkinson’s disease (PD) is a neurodegenerative disorder that presents with a variety of motor and non-motor symptoms[1]

  • We demonstrated the therapeutic effects of anti-Repulsive guidance molecule-a (RGMa) antibodies on the pathology in an animal model of PD

  • Both the intraventricular treatment with polyclonal antiRGMa antibodies and the intravenous treatment with humanized monoclonal anti-RGMa antibodies suppressed the decrease in the number of dopaminergic neurons and the accumulation of microglia/macrophages induced by MPTP administration

Read more

Summary

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder that presents with a variety of motor and non-motor symptoms[1]. Repulsive guidance molecule-a (RGMa) expression is increased in the SN in PD2. Accumulating studies in neurological diseases spinal cord injury (SCI) and multiple sclerosis (MS) demonstrate that increased expression of RGMa inhibits axon regeneration and functional recovery in the injured CNS3–6. RGMa can be an inhibitory factor of neuroplasticity in neurodegenerative diseases. RGMa has a diverse physiological function, such as to inhibit axon growth[10,11,12]. In adult rats with SCI, RGMa express around the lesion site both in neurons and nonneuronal cells, such as oligodendrocytes and microglia. Loss of function by local treatment with RGMa-neutralizing antibodies significantly promotes axon regeneration after SCI10. The antibody-based inhibition of RGMa facilitates axonal growth, ameliorates inflammation, and increases remyelination in models of MS13,14.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call